|
|
|
|
|
|
|
Random, Semi-Targeted Integration In Cell Line Development
|
|
|
Trying to decide what integration method is best for your cell line development (CLD) program? Comparing random integration with semi-targeted (i.e. Transposase) integration side by side, this whitepaper demonstrates that clones developed using random integration often result in higher expression levels, improved growth characteristics, and superior process robustness compared to semi-targeted systems. While semi-targeted approaches may offer precision, they may fall short in overall efficiency and productivity — especially in late-stage manufacturing. If you're selecting an integration method for your CLD program, download this whitepaper today to access data-backed insights to inform a more confident, future-proofed decision.
|
|
|
|
|
|
|
Explore the five essential features your CLD platform must provide — speed, productivity, quality, stability, and flexibility — and consider how our enhanced platforms can help you overcome common development hurdles and unlock the full potential of your biologics pipeline.
|
|
|
|
|
Backed by biologics development experience and a comprehensive analytics suite, the enhanced AbZelectPRO™ CLD platform streamlines the IND pathway — accelerating clinical progression and enabling efficient production of antibodies as well as complex, hard-to-express molecules and next-generation therapeutics. Check out this latest scientific poster to learn how.
|
|
|
|
|
|
|
By leveraging integrated partnered technologies with Revvity and ProteoNic Biosciences, we enable rapid, high-performing workflows that take you from DNA to research cell bank (RCB) generation in as little as 10 weeks, achieving titers of up to 10 g/L.
|
|
|
|
|
|
|
October 21, 2025 - 8:30 AM PDT | 11:30 AM EDT | 4:30 PM BST
Join cell line development experts from Abzena, Revvity, and ProteoNic Biosciences for a live Q&A panel-style webinar that will explore how flexible, next-generation cell line platforms, like AbZelectPRO™, deliver higher productivity, rapid timelines, and regulatory confidence, offering developers a de-risked and streamlined path to the clinic. Learn more.
|
|
|
|
|
